Management of patients with advanced secondary hyperparathyroidism: The Japanese approach

Nephrology Dialysis Transplantation

Volumn 17, Issue 9, 2002, Pages 1553-1557

  Fukagawa, Masafumi ^a,b   Kazama, Junichiro ^a   Shigematsu, Takashi ^a  

^a Kobe University   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcitriol pulse therapy; Hyperparathyroidism; Parathyroid hyperplasia; Parathyroidectomy; Percutaneous ethanol injection therapy; Ultrasonography

Indexed keywords

22 OXACALCITRIOL; ADENOVIRUS VECTOR; ALCOHOL; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; CALCIUM CHANNEL STIMULATING AGENT; PARATHYROID HORMONE; VITAMIN D DERIVATIVE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG PULSE THERAPY; HUMAN; IMAGING SYSTEM; JAPAN; KIDNEY TRANSPLANTATION; MORPHOLOGY; NODULAR HYPERPLASIA; NONHUMAN; PARATHYROID GLAND; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; VIRAL GENE DELIVERY SYSTEM;

EID: 0036714960     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.9.1553     Document Type: Article

References (50)

1. Renal osteodystrophy
2. Recent progress in management of secondary hyperparathyroidism of chronic renal failure
3. Which is the preferred treatment of advanced hyperparathyroidism in a renal patient? I. Medical intervention is the primary option in the treatment of advanced hyperparathyroidism in chronic renal failure
4. Which is the preferred treatment of advanced hyper-parathyroidism in a renal patient? II. Early parathyroidectomy should be considered as the first choice
5. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: Results of a preliminary study
6. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor
7. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism
8. RenaGel, a non-absorbed calcium- and aluminium-free phosphate binders, lowers serum phosphorus and parathyroid hormone
9. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure
10. Cell biology of parathyroid hyperplasia in uremia
11. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patient
12. Presence of sonographically detectable parathyroid glands can predict resistance to oral pulse-dose calcitriol treatment of secondary hyperparathyroidism
13. DANN ploidy pattern of parathyroid parenchymal cells in renal secondary hyperparathyroidism with relapse
14. Decreased 1,25-dihydroxyvitamin D3 receptor density associated with a more severe form of parathyroid hyperplasia in chronic uremic patients
15. 2+ sensing receptor in primary and uremic secondary hyperparathyroidism
16. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism
17. Correlation of enhanced cell proliferation with decreased density of vitamin D receptor in situ in parathyroid hyperplasia in chronic dialysis patients
18. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia
19. Clonal analysis of nodular hyperplasia in renal hyperparathyroidism
20. Progression of uremic hyperpara-thyroidism involves allelic loss on chromosome 11
21. 2+-sensing receptor gene in human parathyroid tumors
22. Vitamin D receptor as a candidate tumor-suppressor gene in severe hyper-parathyroidism of uremia
23. Genetic abnormalities in parathyroid nodules of uremic patients
24. Recurrent renal hyperparathyroidism and DNA analysis of autografted parathyroid tissue
25. Histology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism
26. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure
27. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis
28. The oral 1,25-dihydroxyvitamin pulse therapy in hemodialysis patients with severe secondary hyperparathyroidism
29. Phosphorus restriction prevents parathyroid gland growth: High phosphorus directly stimulates PTH secretion in vitro
30. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro
31. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro
32. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: Role of dietary phosphate
33. Value of parathyroid sonography in secondary hyperparathyroidism
34. Usefulness of ultra-sonographic power-Doppler imaging of parathyroid hyperplasia in renal hyperparathyroidism
35. Surgical significance of supernumerary parathyroid glands in renal hyperparathyroidism
36. Imaging of the parathyroid in chronic renal failure: Diagnostic and therapeutic aspects
37. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis
38. Surgican management of secondary hyperparathyroidism
39. Medical and surgical aspects of parathyroidectomy
40. Minimally invasive parathyroidectomy facilitated by intraoperative nuclear mapping
41. Minimally invasive radioguided parathyroidectomy
42. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patient
43. Resistance to vitamin D in chronic renal failure
44. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy (PEIT) guided by color Doppler flow mapping in chronic dialysis patients
45. Selective percutaneous ethanol injection therapy (PEIT) of parathyroid in chronic dialysis patients-the Japanese strategy
46. Direct injection of calcitriol into parathyroid hyperplasia in chronic dialysis patients with severe parathyroid hyperfunction
47. Ultrasound-guided direct maxacalcitol injection into parathyroid glands in chronic dialysis patients with severe secondary hyperparathyroidism - Induction of apoptosis in hyperplastic parathyroid cells
48. Successful in vivo gene transfer into parathyroid glands with adenoviral vector delivered by selective injection in rats
49. Effects of percutaneous injection therapy (PIT) using 1,25-dihydroxyvitamin D3 (D3) and calcimimetics (KRN 568) in rats with secondary hyperparathyroidism in uremia
50. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma